Controllable Single and Double Difluoromethylene Insertions into C-Cu Bonds: Copper-Mediated Tetrafluoroethylation and Hexafluoropropylation of Aryl Iodides with TMSCFH and TMSCFBr.

J Am Chem Soc

Key Laboratory of Organofluorine Chemistry, Center for Excellence in Molecular Synthesis, Shanghai Institute of Organic Chemistry, University of Chinese Academy of Sciences, Chinese Academy of Sciences, 345 Ling-Ling Road, Shanghai 200032, China.

Published: July 2022

The selective difluoromethylene insertion into a C-Cu bond is a challenging task and is currently limited to either a single CF insertion into CuCF or double CF insertions into CuCF (or ()-CFCF = CFCu). Achieving both selective single and double CF insertions into the same C-Cu bond is even more difficult. Herein, highly controllable single and double CF insertions into CuCFH species with a TMSCFBr reagent have been described, affording two previously unknown fluoroalkylcopper species "Cu(CF)CFH" ( = 1 and 2) independently under different reaction conditions. This work represents the first example of both single and double CF insertions into the same C-Cu bond in a highly selective manner. The synthetic value of the obtained "Cu(CF)CFH" ( = 1 and 2) species is demonstrated by their reactions with aryl iodides, halogenation agents, and cinnamyl chloride, which enables the direct transfer of HCFCF and HCFCFCF moieties into organic molecules. The key to controllable fluorocarbon chain elongation from C to C and from C to C is presumably attributed to the different reactivities of "Cu(CF)CFH" species ( = 0, 1, 2 and 3) and the loading of the TMSCFBr reagent.

Download full-text PDF

Source
http://dx.doi.org/10.1021/jacs.2c03104DOI Listing

Publication Analysis

Top Keywords

single double
16
double insertions
16
insertions c-cu
12
c-cu bond
12
controllable single
8
aryl iodides
8
tmscfbr reagent
8
"cucfcfh" species
8
double
5
insertions
5

Similar Publications

Background: Mivelsiran (ALN-APP) is an investigational, intrathecally administered RNA interference therapeutic designed to lower levels of amyloid-β (Aβ) peptide, a key driver of Alzheimer's disease (AD) and cerebral amyloid angiopathy (CAA) pathogenesis, by reducing upstream production of amyloid precursor protein (APP). We report additional safety, pharmacodynamic, and biomarker data from the double-blind, placebo-controlled, single ascending dose part of the ongoing mivelsiran Phase 1 study (NCT05231785).

Method: Patients with early-onset AD (symptom onset <65 years of age, Clinical Dementia Rating global score 0.

View Article and Find Full Text PDF

Background: Transcutaneous stimulation of the auricular branch of the vagus nerve (tVNS) was administered to participants diagnosed with mild cognitive impairment (MCI) to improve word-list memory (primary outcome) and other cognitive skills.

Method: A randomized, double-blind, placebo-controlled crossover design was used for this trial. Participants with MCI (n = 59) were sorted into one of two sequences: Sham-tVNS or tVNS-Sham.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: VG-3927 is a highly potent, selective, brain penetrant, oral small molecule TREM2 agonist that is currently under development for the treatment of Alzheimer's disease (AD). TREM2, a receptor expressed on microglia in the brain is critical to microglial function in health and in disease. Among microglia-associated AD risk genes, partial loss-of-function variants of TREM2 confer 2-3 fold increase in risk for developing AD, motivating efforts to identify pharmacological agonists targeting TREM2 as a therapeutic option.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Novo Nordisk A/S, Søborg, Denmark.

Background: Evidence suggests glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have therapeutic potential in Alzheimer's disease (AD). Cumulative evidence has indicated a potential reduction in cognitive decline in people with AD, while real-world evidence has shown decreased dementia risk in patients with type 2 diabetes. Non-clinical data reveal that GLP-1RAs impact neuroinflammation and other biological processes believed to be involved in AD pathophysiology, including effects on central and peripheral immune cells.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Prothena Biosciences Inc., Brisbane, CA, USA.

Background: Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by the presence of brain amyloid beta (Aβ) plaques and stages of memory loss, cognitive decline, psychological and psychiatric changes, inability to perform activities of daily living, dementia, and eventually death. Recent evidence demonstrates the slowing of clinical decline with plaque-clearing, anti-Aβ monoclonal antibodies. PRX012 is a humanized monoclonal antibody that targets and clears known pathogenic forms of Aβ in development for subcutaneous (SC) use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!